202 Users Online
Tryptamines API Market Segmented by GMP and Non-GMP Grade in Natural, Synthetic and Bio-Synthetic Sources - GMP Grade Tryptamines APIs held 91.9% Market Share
Revenue from the global tryptamines API market stood at US$ 613.1 million in 2022, with the market estimated to surge ahead at a CAGR of 11.7% to reach a valuation of US$ 2 billion by the end of 2033. As assessed by Persistence Market Research, GMP-grade tryptamines APIs are expected to account for a market value of US$ 621 million in 2023.
The global market for tryptamines APIs expanded at a historic CAGR of 8.9% in the last 5 years from 2017 to 2022.
A monoamine alkaloid called tryptamine can be found in mammals, fungi, and plants. It resembles amino acid tryptophan structurally and has an indole ring structure. Tryptamine, which is assumed to act as a neuromodulator or neurotransmitter, is found in small amounts in mammal brains.
The chemical structure of tryptamine serves as the foundation for the class of substances collectively known as tryptamines. Numerous biologically active substances, such as psychedelic drugs and neurotransmitters, are included in this class. Along with mental health issues and drug abuse, neurological ailments carry a heavy burden.
Ironically, the fact that more individuals are living through their seventies and eighties is contributing to the growth of these diseases. The main causes of neurological illnesses are Parkinson's disease, epilepsy, dementia, strokes, and headache conditions, which stimulate the market for tryptamine APIs.
Tryptamine exhibits an anti-cancer effect in several cultured cancer cells by inhibiting TrpRS enzymatic activity and downregulating TrpRS expression. As a result, tryptamine at cytotoxic levels can stop cancer. Tryptamine was shown to slow the growth of tumors and their diameters in vivo. Because of this application, tryptamine APIs are now in high demand.
The most popular hallucinogens are psilocybin and lysergic acid amide (LSA). Both are members of the chemical family tryptamine. There may be further tryptamines that are beneficial against clusters, such as LSD, without any hallucinogenic side effects. Future changes for treating other types of illnesses may result in increasing demand for tryptamines APIs.
The IHS Migraine Awareness Campaign focuses on educating healthcare professionals and providing them with the crucial knowledge they need to help and manage migraine sufferers. An increase in migraine awareness may lead more people to seek treatment, which will drive the market for tryptamine APIs.
Tryptamines API Market Size (2022)
US$ 613.1 Million
Projected Market Value (2033)
US$ 2 Billion
Global Market Growth Rate (2023-2033)
Market Share of Top 5 Countries
“Increasing Prevalence of Migraine Disorders”
One of the most prevalent neurologic illnesses, migraine affects more than one billion people annually and has a high prevalence and morbidity, particularly in females and young adults. Stress, sleep difficulties, and even suicide are among the comorbidities that migraine sufferers are linked to. Numerous social and biological risk factors, including hormonal imbalances, genetic and epigenetic effects, as well as cardiovascular, neurological, and autoimmune illnesses, have been proposed as a result of the complex and mostly unknown mechanisms underlying migraine development.
Among the most prevalent disorders of the neurological system are headache disorders, which are characterized by persistent headaches. A selected number of primary headache diseases, such as migraine, tension-type headache, and cluster headache, are characterized by the presence of a painful and incapacitating headache itself.
Analgesics, anti-emetics, certain anti-migraine medications, and preventive medications are the primary kinds of medications used to treat headache disorders. Chronic migraine treatment is a dynamic and quickly developing field of study. Discoveries in this area could lead to more accurate diagnoses and individualized treatments for this condition, which would increase the demand for tryptamine APIs.
The study of the neurological effects of psychoactive chemicals, especially tryptamine psychedelics, has grown because of the belief that tryptamine psychedelics can be therapeutically beneficial due to their molecular similarity. Tryptamines mostly have a hallucinogenic effect. Traditional hallucinogens (psychedelics) cause hallucinations by mediating particular serotonin-receptor actions. These substances imitate the effects of more well-known drugs like 2C-B, LSD, and DMT but may still have some stimulant activity. Tryptamines such as N, and N-dimethyltryptamine (DMT) appear to be becoming more popular in the United States.
“Huge Capital Investment for API Manufacturing”
The investment cost for manufacturing tryptamine APIs depends on various factors. These costs depend on location, infrastructure, size, the capacity of manufacturing machines, and the degree of automation. The sophistication of any manufacturing unit also depends on the degree of containment, quality of equipment within the facility, and level of cGMP standards.
These all result in high investment expenses. No company would compromise on the quality and standards necessary for the production of tryptamine APIs. Utilizing quality standards requires significant financial outlay. The license fee for that specific pharma business is a significant additional expense in manufacturing.
Processes such as analytical screening and quality assurance require time. Scale-up processes require high-capacity equipment that is maintained to ensure zero containment during the batches of manufacturing. Raw materials are the building blocks for APIs, and hence, the quality of raw materials matters in manufacturing them. Huge capital investments that are needed for API manufacturing will hinder the growth of tryptamines API manufacturing.
Why is the United States Tryptamines API Market Surging Ahead?
“Need to Treat High Incidence of Migraine Problems”
The United States accounted for 92.0% market share in the North American market in 2022. North America is expected to account for the biggest share of the global market for tryptamines APIs. This is a result of the region's increased need for specialized pharmaceuticals and a rise in the prevalence of migraine issues among the population.
Additionally, pharmaceutical companies' investments and the rising importance of generics are anticipated to drive market expansion across the region.
What Makes Germany a Lucrative Market for Tryptamines API Manufacturers?
High Investments in R&D Projects”
Germany held 21.6% share of the Europe tryptamines API market in 2022. Germany provides a wide range of advantages, excellent service, and simple access to healthcare. This might be ascribed to an increase in R&D project investments as well as the presence of significant regional market participants.
Additionally, it is projected that the expansion of this market will be aided by the growth of the biopharmaceutical industry.
Why is China a Prominent Market for Tryptamines APIs?
“Large Volume Production of APIs in China”
China a market share of 62.4% of the East Asian market for tryptamines APIs in 2022.
Chinese API producers are obtaining globally renowned GMP accreditation. China's Food and Drug Administration (CFDA) has recently passed a series of new laws governing the registration of API facilities, the management of hazardous excipients, and the development of a DMF system that would cover APIs in China.
The pharmaceutical manufacturing sector has a trade fair in China that displays a range of products, including intermediates, packaging tools, specialized chemicals, conventional medications, raw materials, and APIs. Chinese API manufacturers have earned good manufacturing practice (GMP) certifications as well.
Which Tryptamines API Grade is Highly Sought-after?
“GMP Grade APIs Produced in Accordance with Standardised Quality”
GMP grade tryptamines APIs held a market share of 91.9% in 2022.
To reduce production-related hazards, APIs are produced in accordance with established quality standards for clinical use. To ensure that products are regularly produced and monitored in line with quality standards, the good manufacturing practice (GMP) approach is followed.
GMP covers every aspect of manufacturing, such as raw materials, equipment, and workspaces, in addition to personnel training and personal hygiene. A majority of GMP criteria are quite broad and undefined, allowing each producer to choose how to effectively apply the required controls.
Which Source of Tryptamines APIs is Widely Preferred in the Market?
“Synthetic Tryptamine APIs Have Several Therapeutic Properties”
With 50.4% market share, synthetic tryptamines APIs led the market in 2022.
Small molecules, or synthetic chemical APIs, make up a significant portion of the pharmaceutical business and there are numerous small molecule medications that are offered for sale. The development and manufacturing of extremely targeted sumatriptan hydroxytryptamine receptors-ondansetron and alosetron-was created to treat irritable bowel syndrome and decrease nausea and vomiting brought on by cancer chemotherapy and radiotherapy. The monoamine oxidase inhibitor, potent psychedelic, stimulant, and antidepressant properties of tryptamine derivative-methyltryptamine are just a few of its many uses.
Major market players have resorted to expansion as a business growth strategy. Companies looking into potential markets must evaluate their strengths and resources. These could include the mass manufacturing of items meeting GMP standards that have a market in underdeveloped regions.
Similarly, the team at Persistence Market Research has tracked recent developments related to companies offering tryptamines APIs, which are available in the full report.
2023 to 2033
Historical Data Available for
2017 to 2022
US$ Million for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Customization & Pricing
Available upon Request
The global tryptamines API market was valued at US$ 613.1 million in 2022.
Sales of tryptamines APIs are set to exhibit a CAGR of 11.7% and reach US$ 2 billion by 2033.
Demand for tryptamines APIs increased at 8.9% CAGR from 2017 to 2022.
The U.S., China, Germany, Japan, and India account for the most demand for tryptamines API, currently holding 61.4% market share.
The U.S. accounted for 92% share of the North American market in 2022.
China held a share of 62.4% of the East Asia tryptamines API market in 2022.